Text Size

Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers

This study is currently recruiting participants.
Verified November 2012 by Qualissima
Sponsor:
Collaborator:
European Union
Information provided by (Responsible Party):
Qualissima
ClinicalTrials.gov Identifier:
NCT01461174
First received: October 17, 2011
Last updated: November 28, 2012
Last verified: November 2012
History of Changes
  Purpose

The aim of this study is to assess the utility of sleep deprivation as a potential model for prediction of clinical efficacy using a combination of cognitive physiological endpoints.


Condition Intervention Phase
Healthy
 Drug: Modafinil
Drug: Donepezil
Drug: Memantine
 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Effects of 15-day Donepezil and Memantine on Cognitive Functions After a 24 Hours Sleep Deprivation Challenge in Healthy Volunteers: a Double-blind, Placebo-controlled, Randomised, Cross-over Study, With Modafinil as Positive Control

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Qualissima:

Primary Outcome Measures:
  • Change in N-back [ Time Frame: Day 1 and Day 2 for each of the 5 Period ] [ Designated as safety issue: No ]
    The N-back test is both sensitive to SD in healthy volunteers and this test belongs to ADNI cognitive battery which is validated in Alzheimer's disease patients,considered as primary endpoint.


Secondary Outcome Measures:
  • Other cognitive assessments [ Time Frame: Day 1 and Day 2 for each of the 5 Period ] [ Designated as safety issue: No ]
    CANTAB Battery, Memory Rey Auditory Verbal Learning Test (AVLT), Digit Span Test, Verbal Fluency task

  • fMRI [ Time Frame: Day 1 and Day 2 for each of the 5 Period ] [ Designated as safety issue: No ]
    Resting fMRI, fMRI Memory task

  • Rest-EEG and P300 after auditory-ball paradigm Rest-EEG and P300 after auditory-ball paradigm Rest-EEG and P300 after auditory-ball paradigm [ Time Frame: Day 1 and Day 2 for each of the 5 Period ] [ Designated as safety issue: No ]
    Rest-EEG and P300 after auditory-ball paradigm


Estimated Enrollment: 36
Study Start Date: November 2011
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Modafinil
200 mg tablet, single dose
 Drug: Modafinil
200 mg tablet, single dose
Other Name: Modafinil
Experimental: Donepezil
5 mg tablet one per day, 15 days
 Drug: Donepezil
Donepezil or placebo, 5 mg tablet one per day, 15 days
Other Name: Donepezil
Experimental: Memantine
10 mg tablet one per day, 15 days
 Drug: Memantine
Memantine or placebo, 10 mg tablet one per day, 15 days
Other Name: Memantine

  Hide Detailed Description

Detailed Description:

BACKGROUND:

With the inherent difficulty of detecting significant improvements in cognitive performance in normal healthy subjects, it is presently incredibly hard to predict and select efficacious agents early in the drug development process. As such the potential success of novel therapeutic agents for the symptomatic relief of Alzheimer's disease (AD) is largely unknown until the drugs enter relatively large studies, assessing clinical outcome over at least a six month period. To try to overcome this issue, clinical scientists have focused their attention to the development of cognitive endpoints/biomarkers that can be detected in a number of experimental paradigms where cognitive impairments akin to those observed in AD, have been artificially induced.Based on the scientific literature, the use of total Sleep Deprivation in healthy volunteers seems to be a good paradigm to assess potential anti-AD agents.

It is the first multicenter study that combines 3 complementary approaches via a standardization of the sleep deprivation model: cognitive evaluations, imaging and neurophysiology.

STUDY OBJECTIVE(S)

Primary:

The study aim is to assess the utility of sleep deprivation as a potential model for prediction of clinical efficacy using a combination of cognitive physiological endpoints.

The main goals are to test the effects of donepezil and memantine treatment on cognitive functions in young healthy deprived subjects and to assess the potential restoring effect of the two drugs on cognitive functions induce by sleep deprivation.

Secondary:

  • To assess that Sleep Deprivation model results in cognitive impairments
  • To determine the sensitivity of the model by testing the restoring effects of one single dose of modafinil
  • To investigate the reversal effect of modafinil on EEG under sleep deprivation.
  • To investigate the reversal effect of modafinil on fMRI acquisitions under sleep deprivation (subjects that will be included in Toulouse will not have fMRI)
  • To investigate the influence of donepezil and memantine on EEG under sleep deprivation.
  • To investigate the influence of donepezil and memantine on fMRI acquisitions under sleep deprivation (subjects that will be included in Toulouse will not have fMRI).

STUDY DESIGN The study is a phase I, multicentric (Lille, Marseille, Toulouse), randomised, placebo-controlled, cross-over design.

STUDY POPULATION Healthy young male subjects from 25 to 40 years-old (36 subjects randomized)

PRIMARY ENDPOINT(S) AND MAIN SECONDARY ENDPOINT(S)

Primary endpoint:

N-back test

Secondary endpoints:

  • Other cognitive assessments
  • Imaging
  • Neurophysiology
  Eligibility

Ages Eligible for Study:   25 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Demography

  1. Healthy male subjects aged between 25 and 40 years-old inclusive

  2. BMI between 18 kg/m2 to 27 kg/m2

    Health status

  3. The subjects is in good health on the basis of the medical interview (medical history, symptoms) and the physical examination, vital signs and the results of blood chemistry and hematology.
  4. ECG (12 leads) normal (120 < PR < 200 ms; QRS < 120ms; QTcF < 450ms) and/or without clinically relevant impairments as judged by investigator.
  5. The subject does not smoke or smokes a maximum of 5 cigarettes per day and is able to stop during the days of the study.
  6. No claustrophobia (fMRI)

  7. The subject has normal visual and auditory abilities

    Specific to the study

  8. Habitual good sleeping: sleeping on average 6,5 to 9 hours each night in the past month assessed by the Pittsburgh Quality Index (Buysse et al., 1989).
  9. Regular sleeping hours whereby they sleep no later than 1 am and rise before 9 am in the past month assessed by the Pittsburgh Quality Index (Buysse et al., 1989).
  10. The subject can complete the neuropsychological test battery during the training session
  11. The subject corresponds to an extravert personality according to the Eysenck Personality Inventory (Extravert score between 14,4 and 17.9 for subjects aged from 25 to 29 years, between 14,3 and 18 for subjects aged from 30 to 34 years and between 13.6 and 16.7 for the subjects aged from 35 to 40 years) (Smillie et al., 2009)

  12. The subject is right-handed (Edinburgh Handedness Inventory, Imaging measurement condition).

    Regulations

  13. The subjects is able to read and understand the Information Form and comply with the protocol instructions and restrictions
  14. Subjects are covered by a social insurance
  15. Subjects have provided written informed consent

Exclusion Criteria:

Medical history and clinical status

  1. History or presence of psychiatric illness assessed by a psychiatric interview with the Mini-International Neuropsychiatric Interview (M.I.N.I-DSM IV).
  2. History or presence of neurologic illness or others illnesses (general medical interview)
  3. The subject has caffeine intake of greater than 5 drinks per day or excessive energy drink type intake.

  4. The subject has an orthostatic blood pressure reduction > 20 mm Hg, based on a difference of systolic blood pressure between supine and after standing for 3 minutes.

    General conditions

  5. The patient, in the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for any other reason

  6. The subject participates to another clinical trial or is still being within a washout period of a previous clinical trial, or subjects who received more than 4500 euros in the previous 12 months.

    Specific to the study

  7. History or presence of daytime sleepiness with the Epworth scale (score > 10, pathological sleepiness).
  8. History of obstructive sleep apnea assessed by the Berlin questionnaire (positive predictive value is 0.97, specificity= 0.97 and sensitivity = 0.54).
  9. History of periodic leg movements assessed by Restless Legs Syndrome questionnaire (The International Restless Legs Syndrome Study Group, 2003).
  10. Extreme chronotypes: score at the Horne Ostberg scale (< 31 or > 69) (Horne &Östberg, 1976).
  11. Jet lag > 2 hours in the last two weeks.
  12. No time-shifted work during the last month.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01461174

Locations
France
MEDES Recruiting
Toulouse, France
Contact: Arnaud Beck, MD     +33562 17 49 70        
Principal Investigator: Olivier Rascol, MD            
Sponsors and Collaborators
Qualissima
European Union
Investigators
Principal Investigator: Joelle Micallef CIC CPCET
  More Information

No publications provided

Responsible Party: Qualissima
ClinicalTrials.gov Identifier: NCT01461174     History of Changes
Other Study ID Numbers: WP1P001, 2011-000344-25
Study First Received: October 17, 2011
Last Updated: November 28, 2012
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Qualissima:
Sleep deprivation
Cognitive Functions
young male

Additional relevant MeSH terms:
Sleep Deprivation
Dyssomnias
Sleep Disorders
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Mental Disorders
Memantine
Modafinil
Donepezil
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
 Physiological Effects of Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Stimulants
Neuroprotective Agents
Protective Agents
Cholinesterase Inhibitors
Enzyme Inhibitors
Cholinergic Agents
Nootropic Agents

ClinicalTrials.gov processed this record on May 21, 2013